Valuation: Altimmune Inc

Market Cap 537M 477M 446M 407M 764M 51.71B 775M 5.39B 2.09B 26.36B 2.02B 1.97B 84.85B P/E 2026 *
-4.74x
P/E 2027 * -4.34x
Enterprise Value 96.37M 85.71M 80.1M 73.03M 137M 9.28B 139M 968M 375M 4.73B 362M 354M 15.23B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Chairman 78 01/01/2018
Director/Board Member 74 01/08/2004
Director/Board Member 58 01/09/2003
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.05%+1.97%+55.43%+154.28% 44.09B
Weighted average by Cap. +0.17%+1.83%+60.06%+145.78%

Financials

2026 *2027 *
Net sales - -
Net income -99.55M -88.54M -82.74M -75.43M -142M -9.59B -144M -1B -387M -4.89B -374M -366M -15.73B -117M -104M -97.06M -88.49M -166M -11.25B -169M -1.17B -454M -5.73B -438M -429M -18.46B
Net Debt -440M -392M -366M -334M -627M -42.42B -636M -4.42B -1.71B -21.63B -1.65B -1.62B -69.62B -332M -295M -276M -251M -472M -31.95B -479M -3.33B -1.29B -16.28B -1.25B -1.22B -52.42B
Logo Altimmune Inc
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-